Iron Path Capital-backed VION Biosciences: Revolutionizing the Life Science Sector

Iron Path Capital, a private equity firm focused on healthcare and specialty industrials, has partnered with Aldon Corporation, a leading private-label manufacturer and distributor in the healthcare, life science, and STEM education markets. This collaboration marks the first investment of VION Biosciences, Iron Path Capital's go-forward roll-up platform in the life science sector, led by industry veteran Mark Thornton. The acquisition of Aldon Corporation positions VION Biosciences as a key player in the life science industry.

Aldon Corporation specializes in producing specialty, private-label lab chemicals and chemical contract manufacturing solutions for life science applications. Their offerings include blending and repackaging capabilities, as well as kitting solutions for healthcare and STEM education systems. With their unique positioning in the marketplace and established relationships with industry giants, Aldon becomes an attractive first acquisition for Iron Path Capital's broader platform.

VION Biosciences aims to become a leading life science company, providing manufacturing services, mission-critical chemicals, and specialty reagents. These offerings will support scientific discovery, clinical testing, therapeutic development, and innovative solutions in various applications from research to commercialization. VION Biosciences plans to expand its presence globally and build a specialty chemicals platform focused on biopharmaceuticals and molecular diagnostics. This growth will be achieved through organic means and strategic acquisitions.

Scott Mraz, a founding partner of Iron Path Capital, expresses excitement about the partnership with Mark Thornton and the acquisition of Aldon Corporation. He sees these moves as crucial steps in VION's growth strategy.

Mark Thornton, CEO of VION Biosciences, recognizes the immense opportunity in the life science market to support customers in bioprocessing, diagnostics, and education segments. The enriched portfolio of critical reagents, specialty chemicals, and custom services offered by VION Biosciences will cater to the specific needs of these customers. Aldon Corporation's diverse capabilities and broad portfolio of chemical products serve as the catalyst for the creation of VION Biosciences and its future mission.

Aldon Corporation, with its over 50 years of experience, is a leading producer of private-label lab chemicals in the Northeast. As a specialty input manufacturer and producer, Aldon will lay the foundation for VION Biosciences' growth strategy in the biochemical sector. Leveraging unparalleled customer relationships and service, VION Biosciences aims to continue its accelerated growth by focusing on global consolidation and establishing a strong reputation in key industry end markets.

Alex Molinich, President of Aldon Corporation, looks forward to driving Aldon's growth as part of the VION Biosciences Executive team. This collaboration will diversify their reach into untapped markets, enabling them to meet customer needs more effectively.

The transaction with Aldon Corporation marks the fifth platform investment completed by Iron Path Capital, showcasing the firm's commitment to building great businesses in the healthcare and specialty industrials sectors.

Legal advice for the transaction is provided by McDermott, while FORVIS, LLP acts as Iron Path Capital's financial advisor.

About Aldon Corporation

Aldon Corporation is a leading private label chemical manufacturer and distributor, specializing in laboratory chemicals and kitting solutions for a wide range of industries. With over 2,000 different chemicals in 13,000 sizes and configurations, Aldon offers tailor-made, customizable chemical solutions to meet customers' unique requirements. Headquartered in Avon, New York, Aldon is a privately held company.

About Iron Path Capital

Founded in 2021 by Rob Reistetter and Scott Mraz, Iron Path Capital is a private equity firm focused on building exceptional businesses in the healthcare and specialty industrials sectors. With offices in Nashville, TN, and Charlottesville, VA, Iron Path Capital provides strategic leadership, operational expertise, and flexible capital to support management teams in achieving their growth plans.

About VION Biosciences

VION Biosciences is poised to become a top-tier life science platform, offering market-leading manufacturing services, mission-critical chemicals, and specialty reagents. Their value-added services enable scientific discovery, clinical testing, therapeutic development, and innovative solutions across various applications in the biochemical and life science sectors. From research to commercialization, VION Biosciences is committed to revolutionizing the industry.